{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T01:02:42Z","timestamp":1772499762104,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11307-019-01363-0","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T20:11:59Z","timestamp":1557259919000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["PET\/CT Imaging of Human TNF\u03b1 Using [89Zr]Certolizumab Pegol in a Transgenic Preclinical Model of Rheumatoid Arthritis"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3949-1495","authenticated-orcid":false,"given":"Denis R.","family":"Beckford-Vera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Gonzalez-Junca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica S.","family":"Janneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony L.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph E.","family":"Blecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngho","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry F.","family":"VanBrocklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L.","family":"Franc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"1363_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10067-016-3435-2","volume":"36","author":"R Alfonso-Cristancho","year":"2017","unstructured":"Alfonso-Cristancho R, Armstrong N, Arjunji R, Riemsma R, Worthy G, Ganguly R, Kleijnen J (2017) Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clin Rheumatol 36:25\u201334","journal-title":"Clin Rheumatol"},{"key":"1363_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","volume":"11","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Aletaha D (2015) Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 11:276\u2013289","journal-title":"Nat Rev Rheumatol"},{"key":"1363_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26\u201337","journal-title":"Arthritis Rheum"},{"key":"1363_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40744-018-0105-7","volume":"5","author":"GS Kaeley","year":"2018","unstructured":"Kaeley GS, MacCarter DK, Goyal JR et al (2018) Similar improvements in patient-reported outcomes among rheumatoid arthritis patients treated with two different doses of methotrexate in combination with adalimumab: results from the MUSICA trial. Rheumatol Ther 5:123\u2013134","journal-title":"Rheumatol Ther"},{"key":"1363_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nri802","volume":"2","author":"M Feldmann","year":"2002","unstructured":"Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364\u2013371","journal-title":"Nat Rev Immunol"},{"key":"1363_CR6","first-page":"1","volume":"6","author":"KA van Schie","year":"2016","unstructured":"van Schie KA, Heer PO-D, Dijk L et al (2016) Therapeutic TNF inhibitors can differentially stabilize trimeric TNF by inhibiting monomer exchange. Nat Publ Group 6:1\u201310","journal-title":"Nat Publ Group"},{"key":"1363_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","volume":"19","author":"M Feldmann","year":"2001","unstructured":"Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163\u2013196","journal-title":"Annu Rev Immunol"},{"key":"1363_CR8","first-page":"3870","volume":"7","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Zhou Y, Chen H, Wang Z, Tang Z, Liu J (2014) The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials. Int J Clin Exp Med 7:3870\u20133880","journal-title":"Int J Clin Exp Med"},{"key":"1363_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/acr.21600","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis JR, Luijtens K, Kavanaugh A (2012) Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res 64:658\u2013667","journal-title":"Arthritis Care Res"},{"key":"1363_CR10","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2008.091801","volume":"68","author":"EA Haavardsholm","year":"2009","unstructured":"Haavardsholm EA, \u00d8stergaard M, Hammer HB et al (2009) Monitoring anti-TNFalpha treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. Ann Rheum Dis 68:1572\u20131579","journal-title":"Ann Rheum Dis"},{"key":"1363_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","volume":"2","author":"N Goel","year":"2010","unstructured":"Goel N, Stephens S (2010) Certolizumab pegol. Mabs 2:137\u2013147","journal-title":"Mabs"},{"key":"1363_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-016-0245-0","volume":"6","author":"B Lambert","year":"2016","unstructured":"Lambert B, Carron P, D\u2019Asseler Y et al (2016) 99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study. EJNMMI Res 6:1\u20139","journal-title":"EJNMMI Res"},{"key":"1363_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-009-1272-0","volume":"37","author":"G Malviya","year":"2010","unstructured":"Malviya G, Conti F, Chianelli M, Scopinaro F, Dierckx RA, Signore A (2010) Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging 37:386\u2013398","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1363_CR14","first-page":"174","volume":"2","author":"MN Zeman","year":"2012","unstructured":"Zeman MN, Scott PJ (2012) Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging 2:174\u2013220","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1363_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fmed.2018.00339","volume":"5","author":"S Bugatti","year":"2018","unstructured":"Bugatti S, Manzo A, Montecucco C, Caporali R (2018) The clinical value of autoantibodies in rheumatoid arthritis. Front Med (Lausanne) 5:339","journal-title":"Front Med (Lausanne)"},{"key":"1363_CR16","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00259-007-0451-0","volume":"34","author":"Q Cao","year":"2007","unstructured":"Cao Q, Cai W, Li Z-B, Chen K, He L, Li HC, Hui M, Chen X (2007) PET imaging of acute and chronic inflammation in living mice. Eur J Nucl Med Mol Imaging 34:1832\u20131842","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1363_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2967\/jnumed.110.076174","volume":"51","author":"JP Holland","year":"2010","unstructured":"Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51:1293\u20131300","journal-title":"J Nucl Med"},{"key":"1363_CR18","doi-asserted-by":"publisher","first-page":"e0193832","DOI":"10.1371\/journal.pone.0193832","volume":"13","author":"DR Beckford Vera","year":"2018","unstructured":"Beckford Vera DR, Smith CC, Bixby LM, Glatt DM, Dunn SS, Saito R, Kim WY, Serody JS, Vincent BG, Parrott MC (2018) Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS One 13:e0193832","journal-title":"PLoS One"},{"key":"1363_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2967\/jnumed.114.147819","volume":"56","author":"NE Makris","year":"2015","unstructured":"Makris NE, Boellaard R, van Lingen A, Lammertsma AA, van Dongen GAMS, Verheul HM, Menke CW, Huisman MC (2015) PET\/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab. J Nucl Med 56:249\u2013254","journal-title":"J Nucl Med"},{"key":"1363_CR20","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.2967\/jnumed.109.065862","volume":"50","author":"PKE B\u00f6rjesson","year":"2009","unstructured":"B\u00f6rjesson PKE, Jauw YWS, de Bree R et al (2009) Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 50:1828\u20131836","journal-title":"J Nucl Med"},{"key":"1363_CR21","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2967\/jnumed.117.202010","volume":"59","author":"GA Ulaner","year":"2018","unstructured":"Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O\u2019Donoghue JA (2018) First-in-human human epidermal growth factor receptor 2-targeted imaging using 89Zr-pertuzumab PET\/CT: dosimetry and clinical application in patients with breast Cancer. J Nucl Med 59:900\u2013906","journal-title":"J Nucl Med"},{"key":"1363_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/ph5010079","volume":"5","author":"AJ Chang","year":"2012","unstructured":"Chang AJ, DeSilva R, Jain S, Lears K, Rogers B, Lapi S (2012) 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. Pharmaceuticals 5:79\u201393","journal-title":"Pharmaceuticals"},{"key":"1363_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","volume":"72","author":"T Lindmo","year":"1984","unstructured":"Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77\u201389","journal-title":"J Immunol Methods"},{"key":"1363_CR24","doi-asserted-by":"publisher","first-page":"8495","DOI":"10.1073\/pnas.150228297","volume":"97","author":"AM Wu","year":"2000","unstructured":"Wu AM, Yazaki PJ, Tsai SW, Nguyen K, Anderson AL, McCarthy DW, Welch MJ, Shively JE, Williams LE, Raubitschek AA, Wong JYC, Toyokuni T, Phelps ME, Gambhir SS (2000) High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A 97:8495\u20138500","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1363_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jim.2009.06.009","volume":"348","author":"R Palframan","year":"2009","unstructured":"Palframan R, Airey M, Moore A, Vugler A, Nesbitt A (2009) Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 348:36\u201341","journal-title":"J Immunol Methods"},{"key":"1363_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451\u20131458","journal-title":"Drug Discov Today"},{"key":"1363_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1472-6793-7-13","volume":"7","author":"MD Hayward","year":"2007","unstructured":"Hayward MD, Jones BK, Saparov A, Hain HS, Trillat AC, Bunzel MM, Corona A, Li-Wang B, Strenkowski B, Giordano C, Shen H, Arcamone E, Weidlick J, Vilensky M, Tugusheva M, Felkner RH, Campbell W, Rao Y, Grass DS, Buiakova O (2007) An extensive phenotypic characterization of the hTNFalpha transgenic mice. BMC Physiol 7:13","journal-title":"BMC Physiol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-019-01363-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-019-01363-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-019-01363-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T23:50:25Z","timestamp":1588722625000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-019-01363-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1007\/s11307-019-01363-0","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"assertion":[{"value":"7 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}